New York – The US FDA has approved Jevtana, a chemotherapy drug by Sanofi-Aventis that cures prostate cancer. This medication reduces fatalities by 28% and assure 2,5 more month to those whose tumors resist all other treatments. Prostate cancer is the second most common type of male disease, and cause every year 254.000 deaths. It is expected that the drug sale volume should reach 294 million dollars by 2014.